Gamida Cell Ltd. Gains 36.56%

Tue, May 12, 2020 at 05:30 PM

Gamida Cell Ltd. (GMDA:NASDAQ) rocketted at $6.2, representing a gain of 36.6%. On Mon 11 May 20, GMDA:NASDAQ hit a New 2-Week High of $4.54. From Mon 27 Apr 20, the stock recorded 50.00% Up Days and 27.27% Green Days

The share price of the company has been moving sideways in recent weeks.

About Gamida Cell Ltd. (GMDA:NASDAQ)

Gamida Cell Ltd is engaged in the development of cellular and immune therapeutics for cancer and rare genetic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma.

Top 10 Gainers:

CymaBay Therapeutics, Inc. (CBAY:NASDAQ), 127.17%
Novavax, Inc. (NVAX:NASDAQ), 62.53%
Rand Capital Corporation (RAND:NASDAQ), 43.07%
Super League Gaming, Inc. (SLGG:NASDAQ), 41.3%
Babcock & Wilcox Enterprises, Inc. (BW:NYSE), 40.26%
Gamida Cell Ltd. (GMDA:NASDAQ), 36.56%
Naked Brand Group Limited (NAKD:NASDAQ), 34.62%
VectoIQ Acquisition Corp. (VTIQ:NASDAQ), 32.97%
Ritter Pharmaceuticals, Inc. (RTTR:NASDAQ), 32.33%
Grubhub Inc. (GRUB:NYSE), 29.07%